RASHMI KRISHNA MURTHY to Camptothecin
This is a "connection" page, showing publications RASHMI KRISHNA MURTHY has written about Camptothecin.
Connection Strength
0.400
-
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020 06 10; 38(17):1887-1896.
Score: 0.142
-
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019 06; 20(6):816-826.
Score: 0.135
-
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clin Cancer Res. 2023 01 04; 29(1):174-182.
Score: 0.043
-
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discov. 2022 12 02; 12(12):2754-2762.
Score: 0.043
-
Reply to T.J.A. Dekker. J Clin Oncol. 2020 10 01; 38(28):3351-3352.
Score: 0.037